PRECIGEN, INC. reported financial results for the quarter ended March 31, 2026.
“Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 13, 2026, reporting its financial results for the quarter ended March 31, 2026.”
PRECIGEN, INC. — fact timeline
Source-grounded facts extracted from PRECIGEN, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
PRECIGEN, INC. reported financial results for year ended December 31, 2025.
“Precigen, Inc., dated March 25, 2026, reporting its financial results for the year ended December 31, 2025.”
PRECIGEN, INC. issued 54,937,411 shares of common stock of common stock.
“On September 15, 2025, the holders of Precigen, Inc.’s (the “Company’s” and “our”) 8.00% Series A Convertible Perpetual Preferred Stock (“Preferred Stock”) converted 79,000 shares of Preferred Stock (with an aggregate stated value of $79,000,000) into 54,937,411 shares of common stock of the Company, which were delivered to such holders on September 17, 2025”
Jeffrey Perez departed as Senior Vice President, Intellectual Property Affairs at PRECIGEN, INC..
“On September 23, 2024, Precigen, Inc. (the “Company”) announced the separation from employment of Jeffrey Perez, Senior Vice President, Intellectual Property Affairs, effective November 1, 2024.”
Nancy Howell Agee was elected as Director at PRECIGEN, INC..
“As described under Item 5.07 below, at the 2024 Annual Meeting, Nancy Howell Agee was elected to the Board, effective as of July 5, 2024.”
Dean Mitchell departed as Director at PRECIGEN, INC..
“As previously disclosed in the Proxy Statement, Dean Mitchell did not stand for re-election at 2024 Annual Meeting. Accordingly, Mr. Mitchell’s term on the Board ended effective as of July 5, 2024.”
PRECIGEN, INC. reported financial results for first quarter 2024.
“Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 14, 2024, reporting its financial results for the quarter ended March 31, 2024.”
PRECIGEN, INC. reported financial results for the quarter and year ended December 31, 2023.
“Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 19, 2024, reporting its financial results for the quarter and year ended December 31, 2023.”
PRECIGEN, INC. reported financial results for third quarter 2023.
“Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced third quarter 2023 financial results and progress of clinical programs.”
PRECIGEN, INC. reported financial results for the quarter ended June 30, 2023.
“Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated August 9, 2023, reporting its financial results for the quarter ended June 30, 2023.”
PRECIGEN, INC. shareholders approved Approval of the Precigen, Inc. 2023 Omnibus Incentive Plan.
“Proposal 4 - Approval of the Precigen, Inc. 2023 Omnibus Incentive Plan. For Against Abstain Broker Non-Votes 145,378,065 3,088,440 444,504 39,110,863”
PRECIGEN, INC. shareholders approved Non-binding Advisory Resolution Approving the Compensation of the Named Executive Officers.
“Proposal 3 - Non-binding Advisory Resolution Approving the Compensation of the Named Executive Officers. For Against Abstain Broker Non-Votes 142,885,749 5,521,791 503,469 39,110,863”
PRECIGEN, INC. shareholders approved Ratification of the Appointment of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023 at the 2023-12-31 meeting.
“Proposal 2 - Ratification of the Appointment of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023. For Against Abstain 187,098,923 812,924 110,025”
PRECIGEN, INC. shareholders approved Election of Directors.
“Proposal 1 - Election of Directors For Against Abstain Broker Non-Votes Randal Kirk 146,746,009 1,973,895 191,105 39,110,863 Cesar Alvarez 138,469,237 10,324,861 116,911 39,110,863 Steven Frank 140,313,694 8,383,203 214,112 39,110,863 Vinita Gupta 143,223,505 5,292,446 395,058 39,110,863 Fred Hassan 143,676,028 5,012,125 222,856 39,110,863 Jeffrey Kindler 141,867,748 6,832,957 210,304 39,110,863 Dean Mitchell 132,958,522 15,741,660 210,827 39,110,863 Helen Sabzevari 146,444,421 2,185,558 281,030 39,110,863 James Turley 145,231,754 3,464,127 215,128 39,110,863”
PRECIGEN, INC. reported financial results for the quarter ended March 31, 2023.
“Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated May 10, 2023, reporting its financial results for the quarter ended March 31, 2023.”
PRECIGEN, INC. amended License Agreement with Alaunos Therapeutics valued at $75,000 (effective 2023-04-03).
“On April 3, 2023, Precigen, Inc., (the “Company”), entered into an amended and restated exclusive license agreement (the “License Agreement”), with Alaunos Therapeutics (“Alaunos”).”
PRECIGEN, INC. reported financial results for the quarter and year ended December 31, 2022.
“Attached as Exhibit 99.1 is a copy of a press release of Precigen, Inc., dated March 6, 2023, reporting its financial results for the quarter and year ended December 31, 2022.”
PRECIGEN, INC. entered into Underwriting Agreement with J.P. Morgan Securities LLC, as representative of the several underwriters named therein valued at approximately $71.2 million (effective 2023-01-24).
“On January 24, 2023, Precigen, Inc. (“Precigen”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, as representative of the several underwriters named therein (the “Underwriters”), in connection with the underwritten public offering (the "Offering") of 42,857,143 shares (the “Firm Shares”) of Precigen common stock, no par value (“Common Stock”), at a price to the public of $1.75 per share.”
PRECIGEN, INC. reported financial results for third quarter 2022.
“precigen reports third quarter 2022 financial results and progress of clinical programs”
Rutul R. Shah was appointed as Chief Operating Officer at PRECIGEN, INC..
“On September 15, 2022, the Board of Directors (the “Board”) of Precigen, Inc. (the “Company”) approved the appointment of Rutul R. Shah, currently the Company’s Vice President, Head of Operations and Portfolio, to serve as Chief Operating Officer of the Company, effective October 1, 2022.”
James V. Lambert changed role as Interim Principal Accounting Officer at PRECIGEN, INC..
“James V. Lambert, who has served as interim principal accounting officer of the Company since Mr. Osborne's resignation, will step down from that position effective upon Mr. Thomasian's start date, and will continue to serve as Executive Director, Finance for PGEN Therapeutics, Inc., a wholly owned subsidiary of the Company.”
Harry Thomasian Jr. was appointed as Chief Financial Officer at PRECIGEN, INC..
“On October 12, 2021, Precigen, Inc. (the “Company”), announced that Harry Thomasian Jr., age 59, was appointed Chief Financial Officer of the Company, effective October 18, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.